Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

303
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
303
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

230
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
230
Drug Product Performance: In Vitro–In Vivo Correlation01:20

Drug Product Performance: In Vitro–In Vivo Correlation

228
In pharmaceutical development, it's crucial to establish a predictive in vitro–in vivo correlation (IVIVC) for two or more formulations to gain a comprehensive understanding of release properties. IVIVC reduces the need for costly in vivo studies and facilitates the establishment of meaningful dissolution specifications with significant cost savings and decreased regulatory burden. Furthermore, a meaningful IVIVC should predict Cmax and AUC within 20%, aligning with FDA guidance while...
228
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.6K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.6K
Clinically Relevant Drug Product Specifications: Methods of Establishment01:29

Clinically Relevant Drug Product Specifications: Methods of Establishment

201
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
201
Preclinical Development: Overview01:28

Preclinical Development: Overview

5.8K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical Impact of the BIOFIRE® FILMARRAY® Pneumonia Panel in the Veterans Affairs Healthcare System: A Difference-in-Differences Study.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Improving the culture surrounding tracheal aspirates in mechanically ventilated children.

Journal of clinical microbiology·2026
Same author

Planning for the future of the American Society for Microbiology's Health Unit by the Council on Microbial Sciences.

mSphere·2026
Same author

Beyond Accuracy: Methodological Advances for Assessing the Clinical Impact of Infectious Disease Diagnostics.

Open forum infectious diseases·2025
Same author

Uniting disciplines against antimicrobial resistance (AMR): highlights from a multidisciplinary inaugural AMR summit.

Antimicrobial stewardship & healthcare epidemiology : ASHE·2025
Same author

Proceedings of the Clinical Microbiology Open 2024: artificial intelligence applications in clinical microbiology.

Journal of clinical microbiology·2025

Related Experiment Video

Updated: Jan 14, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

11.1K

Navigating and Advancing Market Access for In Vitro Diagnostics: Understanding the Roles of Key Stakeholders and

Brandon K Hill1, Andrea M Prinzi1, J R Kane2

  • 1US Medical Affairs, bioMérieux, Salt Lake City, Utah, USA.

Open Forum Infectious Diseases
|October 24, 2025
PubMed
Summary

Navigating market access challenges is crucial for the widespread adoption of infectious disease diagnostics. Engaging with policymakers and payors through evidence-based advocacy is key to improving patient access to vital diagnostic technologies.

Keywords:
advocacyhealth policyin vitro diagnosticsinfectious diseases diagnosticsmarket access

More Related Videos

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

9.5K
In Vivo Imaging Systems IVIS Detection of a Neuro-Invasive Encephalitic Virus
10:21

In Vivo Imaging Systems IVIS Detection of a Neuro-Invasive Encephalitic Virus

Published on: December 2, 2012

21.3K

Related Experiment Videos

Last Updated: Jan 14, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

11.1K
In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

9.5K
In Vivo Imaging Systems IVIS Detection of a Neuro-Invasive Encephalitic Virus
10:21

In Vivo Imaging Systems IVIS Detection of a Neuro-Invasive Encephalitic Virus

Published on: December 2, 2012

21.3K

Area of Science:

  • Clinical Diagnostics
  • Health Policy and Market Access
  • Antimicrobial Resistance

Background:

  • Rapid and accurate infectious disease diagnostics are critical for antimicrobial stewardship and patient outcomes.
  • Barriers to in vitro diagnostics (IVDs) adoption include high costs, inconsistent reimbursement, and regulatory hurdles.
  • Market access, health policy, and advocacy significantly influence diagnostic technology availability to patients.

Purpose of the Study:

  • To provide an overview of the market access process for in vitro diagnostics (IVDs).
  • To highlight the influence of various stakeholders on diagnostic accessibility.
  • To emphasize the need for coordinated, evidence-based engagement to advance IVD adoption.

Main Methods:

  • Review of key components of the market access process: regulatory pathways, coverage, reimbursement, evidence generation, and stakeholder engagement.
  • Analysis of the roles of healthcare providers, payors, patients, and policymakers.
  • Emphasis on the importance of advocacy by clinicians, pharmacists, and laboratory professionals.

Main Results:

  • Understanding the market access landscape is essential for overcoming adoption barriers for new diagnostics.
  • Active participation of healthcare professionals in policy and advocacy is vital for influencing regulation and reimbursement.
  • Coordinated communication strategies are necessary to effectively engage with regulatory bodies, payors, and professional societies.

Conclusions:

  • Advancing the accessibility of in vitro diagnostics requires strategic engagement with market access components.
  • Evidence-based advocacy by clinical and laboratory professionals is pivotal for successful policy and reimbursement.
  • Collaboration among stakeholders is essential to ensure timely patient access to innovative diagnostic solutions.